EUVIMEDEUVIMED entdecken
Crossref

Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis

Yu Wang, Huibin Yin, Zheng Li, Hao Wu, Qianhao Wang, Xingyu Chen, Liya Mao, Yuemeng Wu, Shangshang Wang, Haihong Qin, Chaoying Gu, Xu Yao und 1 weitere

Journal of Investigative Dermatology · 2025

DOI: 10.1016/j.jid.2025.02.145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Yu Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shanghai Institute of Dermatology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan Unive…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Transcriptome, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Huashan Hospital, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with atopic dermatitis (AD) exhibit significant blood transcriptome alterations, reflecting systemic inflammation. The effects of abrocitinib, a Jak1 inhibitor, on the blood transcriptome of AD remain unclear. This study aimed to investigate abrocitinib's effects on the blood transcriptome in patients with AD and identify transcriptomic predictors of treatment efficacy. Blood cell mRNA sequencing was conducted on 31 patients with AD at baseline and 4 and 12 weeks of 100 mg abrocitinib daily treatment. Differential gene expression, immune infiltration, and weighted gene coexpression network analyses were performed, along with correlation analysis of transcriptomic data and clinical traits. We observed that abrocitinib treatment significantly improved clinical signs of AD. Correspondingly, blood transcriptome normalization, including downregulation of T helper 2, T helper 1, and eosinophil and an increase in type 1 regulatory T-cell abundance, rapidly occurred by week 4, with slight rebound by week 12. Higher baseline eosinophil counts predicted greater transcript normalization. Weighted gene coexpression network analyses identified an efficacy-related gene module, leading to a 5-gene (PLIN2, CAT, CLC, RAB44, and SMPD3) efficacy-predictive model, which was validated in another independent cohort of 30 patients with AD treated with abrocitinib. In conclusion, abrocitinib treatment resulted in rapid and extensive normalization of the dysregulated blood transcripts in AD, which was associated with its clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicTranscriptomePyrimidinesHumansFemaleMaleAdultTreatment OutcomeGene Expression ProfilingYoung AdultMiddle AgedAdolescentGene Regulatory NetworksSulfonamides

Stichwörter der Autor:innen

AbrocitinibAtopic dermatitisBlood transcriptomeRNA-seq

Substanzen

abrocitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, Shanghai Institute of Dermatology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union…
  • Department of Dermatology, Shanghai Institute of Dermatology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People's Republic of China. Electronic address: liwei…

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • Huashan Hospital
  • Shanghai Municipal Health Commission
  • National Natural Science Foundation of China
  • Health and Family Planning Commission of Sichuan Province
  • Shanghai Shenkang Hospital Development Center
  • Shanghai Municipal Education Commission

Zitieren

APA

Wang, Y., Yin, H., Li, Z., Wu, H., Wang, Q., Chen, X., Mao, L., Wu, Y., Wang, S., Qin, H., Gu, C., Yao, X., & Li, W. (2025). Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2025.02.145

Vancouver

Wang Y, Yin H, Li Z, Wu H, Wang Q, Chen X, et al. Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2025.02.145

BibTeX
@article{Wang2025,
  author = {Wang, Yu and Yin, Huibin and Li, Zheng and Wu, Hao and Wang, Qianhao and Chen, Xingyu and Mao, Liya and Wu, Yuemeng and Wang, Shangshang and Qin, Haihong and Gu, Chaoying and Yao, Xu and Li, Wei},
  title = {Blood Transcriptome Signature as Indicator and Predictor for Efficacy of Abrocitinib in Treatment of Atopic Dermatitis},
  journal = {Journal of Investigative Dermatology},
  year = {2025},
  doi = {10.1016/j.jid.2025.02.145}
}
Kostenlos starten →